TFF Pharmaceuticals (NASDAQ:TFFP)‘s stock had its “buy” rating reissued by analysts at Maxim Group in a research note issued on Wednesday, reports. They presently have a $18.00 price target on the stock. Maxim Group’s price objective suggests a potential upside of 18.97% from the stock’s current price.

TFFP has been the topic of several other research reports. Roth Capital lifted their price objective on shares of TFF Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Zacks Investment Research upgraded shares of TFF Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, September 9th.

Shares of TFFP traded up $0.16 during mid-day trading on Wednesday, hitting $15.13. The company’s stock had a trading volume of 2,541 shares, compared to its average volume of 209,105. The firm has a 50-day moving average price of $11.93 and a 200 day moving average price of $6.82. The stock has a market capitalization of $325.79 million and a price-to-earnings ratio of -4.88. TFF Pharmaceuticals has a fifty-two week low of $3.44 and a fifty-two week high of $16.26.

TFF Pharmaceuticals (NASDAQ:TFFP) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.02. Equities research analysts forecast that TFF Pharmaceuticals will post -0.81 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Sigma Planning Corp increased its position in TFF Pharmaceuticals by 5.1% during the second quarter. Sigma Planning Corp now owns 94,150 shares of the company’s stock worth $542,000 after acquiring an additional 4,600 shares during the period. BlackRock Inc. increased its position in TFF Pharmaceuticals by 77.8% during the first quarter. BlackRock Inc. now owns 22,134 shares of the company’s stock worth $84,000 after acquiring an additional 9,682 shares during the period. Gagnon Securities LLC bought a new position in TFF Pharmaceuticals during the second quarter worth $1,268,000. Finally, Nantahala Capital Management LLC increased its position in TFF Pharmaceuticals by 47.9% during the second quarter. Nantahala Capital Management LLC now owns 856,517 shares of the company’s stock worth $4,934,000 after acquiring an additional 277,300 shares during the period. 8.97% of the stock is currently owned by institutional investors.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Read More: What is the Consumer Price Index (CPI)?

Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with's FREE daily email newsletter.